Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > The reasons for the delay....
View:
Post by wildbird1 on Mar 28, 2024 8:28am

The reasons for the delay....

Some people on this board pretend that TLT didn't explain the reason for the delay.

I disagree...
In the Jan15,2024 PressRelease TLT said...
'' Based on the FDA's feedback, the Company is currently working with the Clinical Study Sites(''CSS''), a central pathology organization, a biostatistics organization and a regulatory consulting organization to update the the pre-BTD with clinical data clarifications identified by the FDA''.
These steps have to be done in chronological order (TLT has to wait for each organization data,before passing the data to the next organization).
At this point in time TLT can't ask these organizations to rush things, making a mistake at the present time would be very costly for TLT and all of us investors.
Note1)
TLT doesn't need to repeat the above in each PressRelease.

Note2)
1)For those that have warrants, remember that R.Dumoulin has also warrants.
2)There is still time to get BTD approval before these warrants expire. 

I like to repeat my prefered quote from Warrent Buffet...
'' No matter how great the talent or efforts, some things just take time''.
Comment by Longholder99 on Mar 28, 2024 8:48am
Well said Wildbird.   People love to pile on.  Assume the worst.  Speculate in the absence of facts or knowledge.  Clearly the MBA's with years of experience with on time or even early execution of new biotech approval through FDA and HC channels are all on this board.  Shame that the Doctors, Phd's, and P.Eng at Theralse don't measure up to the standard ...more  
Comment by Alamir1111 on Mar 28, 2024 9:00am
        News   Press Releases   Theralase Provides Update on Phase II Bladder Cancer Study V.TLT | ...more  
Comment by Dumbeldorfwhite on Mar 28, 2024 9:05am
You conveniently left out the plan for submission early Q1
Comment by enriquesuave on Mar 28, 2024 9:33am
Obviously management estimates timeline based on what CSS's tell them.  If the CSS's have delays, then it's beyond TLT's reach.  Each delaybrings us closer and closer.    
Comment by Camphikefish on Mar 28, 2024 9:48am
Folks here have certainly clarified with good explanations as to why the preBTD was delayed and BTD to follow. So I am satisfied especially with the former news release that was brought back to light. I have no complaints and only wanted more clear answers. The one thing I wish I could square up is why no new patient enrollments. This is not a complaint this is only a question that makes no sense ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250